Precise differentiation and diagnosis of prostate cancer is necessary to unveil the different molecular expressions during varying stages of this second most frequent malignancy among men worldwide.1–3 Although regarded as the first-line test for prostate cancer diagnostics, total PSA (tPSA) screening appears to be controversial with high false-positive outcomes. This evidence concerns the gene KLK3 and Familial prostate cancer.